Literature DB >> 2677394

Oligodeoxynucleotides as anti-sense inhibitors of gene expression: therapeutic implications.

M Rothenberg1, G Johnson, C Laughlin, I Green, J Cradock, N Sarver, J S Cohen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2677394     DOI: 10.1093/jnci/81.20.1539

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  7 in total

Review 1.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

2.  CD, absorption and thermodynamic analysis of repeating dinucleotide DNA, RNA and hybrid duplexes [d/r(AC)]12.[d/r(GT/U)]12 and the influence of phosphorothioate substitution.

Authors:  C L Clark; P K Cecil; D Singh; D M Gray
Journal:  Nucleic Acids Res       Date:  1997-10-15       Impact factor: 16.971

Review 3.  Growth factors in gliomas: antisense and dominant negative mutant strategies.

Authors:  J W Campbell; I F Pollack
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

4.  Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.

Authors:  A R Thierry; A Dritschilo
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

5.  Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides.

Authors:  G Citro; D Perrotti; C Cucco; I D'Agnano; A Sacchi; G Zupi; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

6.  The second Bagshawe lecture. Matching basic research to the management of cancer: the view from the other side of the fence.

Authors:  J A Wyke
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

Review 7.  Antisense technology for cancer therapy: does it make sense?

Authors:  G Carter; N R Lemoine
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.